Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Advancement of two late-stage pipeline therapies raises new prospects for dry eye syndrome

Current treatment options for DES in the US are mainly dominated by a mix of prescription, off-label, and over-the-counter (OTC) products. Credit: Shutterstock + liza54500



  • dry eye syndrome
Close
Close
Close

Go Top